"concurrent use of antithrombotic agents 3,5."
"Amyloid related imaging abnormalities (ARIA) represent a variety of imaging features identified in patients with Alzheimer disease being treated with novel amyloid lowering (anti-amyloid) therapies such as the monoclonal antibodies lecanemab, donanemab, and aducanumab (discontinued in 2024 after initial FDA approval) 1-4."
"ARIA-E: 13%"
"ARIA-H: 17%"
"ARIA-E: 24%"
"ARIA-H: 31%"
"ARIA-E: 35%"
"ARIA-H: 20%"
"ARIA-E"
"ARIA-E (E for oedema) is characterised by the presence of 1:"
"parenchymal oedema (ARIA-E oedema)"
"sulcal effusions (ARIA-E effusions)"
"Although ARIA-E can occur bilaterally, it is most frequently (~two-thirds) unilateral 1."
"ARIA-H"
"ARIA-H (H for haemorrhage) is usually seen in combination with ARIA-E and is characterised by the presence of 1,4:"
"ARIA-H (H for haemorrhage) is usually seen in combination with ARIA-E and is characterised by the presence of 1,4:"
"Notably, anti-amyloid drugs were FDA approved using T2* for monitoring, instead of more sensitive sequences such as SWI 10."
"Grading of ARIA-E and ARIA-H can be performed in a reproducible and standardised way, to allow safe continuation or reasonable discontinuation of therapy with an amyloid-lowering therapy 11."
"Grading of ARIA-E and ARIA-H can be performed in a reproducible and standardised way, to allow safe continuation or reasonable discontinuation of therapy with an amyloid-lowering therapy 11."
"ARIA-E"
"ARIA-H - microbleed subtype"
"ARIA-H - cortical superficial siderosis subtype"
"Both parenchymal oedema and sulcal effusions forms of ARIA-E are usually transient resolving over a number of months 1. Blood products, in contrast, usually do not."
"the number of APOE ε4 alleles (also known to correlate with increased risk of cerebral amyloid angiopathy)"
"ARIA-E"
"ARIA-H"
"ARIA-E"
"ARIA-H - microbleed subtype"
Expected headings
"ARIA-E"
"ARIA-H"
"Staging"
"ARIA-E"
"ARIA-H - microbleed subtype"
"ARIA-H - cortical superficial siderosis subtype"
"In most instances, ARIA is detected incidentally on imaging. Some patients describe various symptoms related, presumably, to cerebral oedema and irritation including headaches, vomiting, confusion, focal neurological deficits, and gait disturbance 4."
"moderate: FLAIR hyperintensity of 5-10 cm extension or more than 1 FLAIR hyperintensity overall; generally"
"the imaging features of ARIA are essentially identical, with the only real distinguishing feature being clinical context; namely, ARIA occurs in individuals being treated with amyloid lowering agents"
"severe: FLAIR hyperintensity extending >10 cm, solitary or multifocal"
"perilesional oedema (e.g. around metastasis, primary tumour, abscess)"